Scandinavian life science sector attracts investors
A new report from Stockholm-based venture capital investor Industrifonden shows a great interest for life science companies in Scandinavia, with a total investment of $2.4bn from 2014 to the third quarter of 2016. One of several trends is that venture capital funds this year have increased focus on IPO’s, and this trend looks set to continue.These figures and trends are reported in Scandinavian Life Science Funding Report, 2014-2016, commissioned by Industrifonden, which has 15 life science companies in its portfolio. The report is a thorough analysis of the investment landscape and
Industrifonden strengthens its Life Science investment team by recruiting Patrik Sobocki as Investment Manager. Patrik has extensive experience from the pharmaceutical industry, academic research and developing startup companies.Before joining Industrifonden, Patrik Sobocki held the position of European Chief Operating Officer for the business area Real World Evidence at IMS Health, the world’s leading provider of information and technology services to the healthcare industry. The role included responsibility for IMS Health’s M&A strategy within Real World Evidence. At Industrifonden,
The Sweden-based venture capital investor Industrifonden sells its entire holding in Accedo, the global leader in television and video experience services, to SEB Private Equity. In recent years, Accedo has been named one of Sweden's fastest growing companies. The company has SEK 320 million ($40 million) in revenue, more than 100 million users and 400 employees globally. The transaction generates a return of seven times the investment for Industrifonden.Accedo’s TV and video solutions are used by hundreds of millions of people globally. The company has close partnerships with some of the